Ocular Therapeutix Inc (OCUL) financials

NASDAQ · Health Care

$6.97 -4.65% Close Oct 30, 2026 Live

Ocular Therapeutix revenue and earnings by year

Ocular Therapeutix's revenue was $52.0 million in the fiscal year to December 31, 2025, down 18.5% from the year before. Net income was -$266 million, -511.9% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 44.5% a year on average.

RevenueNet income
-$200M-$100M$0
2016201720182019202020212022202320242025

Fiscal years, each labelled by the calendar year it ended in.

Income statement, the last 10 fiscal years

In millions of US dollars except per-share figures. Each column is a fiscal year, named by the month it ended.
Fiscal year toDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
Revenue5264585144174222
Revenue growth-18.5%9.0%13.5%18.3%150.1%311.7%112.4%3.5%1.9%—
Gross profit4558534739152211
Gross margin87.3%91.2%91.0%91.2%89.9%88.0%45.0%76.6%76.2%76.5%
Operating income-270-172-82-79-78-63-86-59-62-43
Operating margin-519.8%-269.6%-141.0%-152.7%-179.3%-361.1%-2029.9%-2970.8%-3220.1%-2296.0%
Net income-266-194-81-71-7-156-86-60-63-45
Net margin-511.9%-303.7%-138.1%-138.0%-15.1%-894.3%-2043.3%-3014.0%-3296.2%-2369.0%
Diluted EPS-$1.42-$1.22-$1.02-$0.97—-$2.56-$2.00-$1.57-$2.20-$1.80
Free cash flow-217-136-76-63-67-54-80-51-59-36

Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open OCUL in Markets.

See also: OCUL returns

No forecast, no recommendation. This page describes Ocular Therapeutix Inc from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.